Urinary Test Score Unchanged by Chronic Prostatitis
|
By LabMedica International staff writers Posted on 25 Apr 2012 |
|
The influence of chronic prostatitis on the potential new biomarkers of prostate cancer (PCa) found in male urinary samples has been determined.
Prostate cancer gene 3 (PCA3) is one of the most promising candidate markers for prostate cancer (PCa) diagnosis and it has been found to be overexpressed in up to 95% of all prostate cancer patients tested and is 60- to 100-less expressed in noncancerous than in cancerous tissues.
Scientists the Hospices Civils de Lyon (France) collected urine specimens for cytological analysis and culture from 38 patients with clinical suspicion of chronic prostatitis whose mean-age was 37.5 years. The specimens were collected between March and June 2010 and a postprostatic massage urine sample was used for the urinary PCA3 test. None of the patients had history of prostate cancer.
The PCA3 and Prostate Specific Antigen (PSA) ribonucleic acid (RNA) were quantified in parallel using the Progensa PCA3 Assay (Gen-Probe; San Diego, CA, USA). Urine samples were considered as noninformative for prostate cells if number of PSA messenger RNA (mRNA) transcripts detected was less than 10,000. A negative PCA3 test was considered if PCA3 score was less than the usual cutoff of 35. The PCA3 test was considered positive if PCA3 score was higher than or equal to 35.
Four patients had an eventual diagnosis of urethritis and all had a PCA3 score less than 5. Among the remaining 34 patients, seven had bacterial chronic prostatitis, 11 had abacterial chronic prostatitis, and 16 had noninflammatory prostatodynia. All these patients had a PCA3 score less than 28, that is, under the cutoff of 35, which is commonly used for prostate cancer diagnosis.
The authors concluded that prostate massage included within the Meares–Stamey four-glass localization test allows informative samples for urinary PCA3 test. The PCA3 score was found to be negative with less than the usual cutoff of 35, in all tested patients, suggesting that PCA3 test can be used as a valuable tool in patients with raised PSA and suspicion of chronic prostatitis to distinguish those patients who will really benefit from prostate biopsy. The study was published in the April 2012 edition of the journal the Prostate.
Related Links:
Hospices Civils de Lyon
Gen-Probe
Prostate cancer gene 3 (PCA3) is one of the most promising candidate markers for prostate cancer (PCa) diagnosis and it has been found to be overexpressed in up to 95% of all prostate cancer patients tested and is 60- to 100-less expressed in noncancerous than in cancerous tissues.
Scientists the Hospices Civils de Lyon (France) collected urine specimens for cytological analysis and culture from 38 patients with clinical suspicion of chronic prostatitis whose mean-age was 37.5 years. The specimens were collected between March and June 2010 and a postprostatic massage urine sample was used for the urinary PCA3 test. None of the patients had history of prostate cancer.
The PCA3 and Prostate Specific Antigen (PSA) ribonucleic acid (RNA) were quantified in parallel using the Progensa PCA3 Assay (Gen-Probe; San Diego, CA, USA). Urine samples were considered as noninformative for prostate cells if number of PSA messenger RNA (mRNA) transcripts detected was less than 10,000. A negative PCA3 test was considered if PCA3 score was less than the usual cutoff of 35. The PCA3 test was considered positive if PCA3 score was higher than or equal to 35.
Four patients had an eventual diagnosis of urethritis and all had a PCA3 score less than 5. Among the remaining 34 patients, seven had bacterial chronic prostatitis, 11 had abacterial chronic prostatitis, and 16 had noninflammatory prostatodynia. All these patients had a PCA3 score less than 28, that is, under the cutoff of 35, which is commonly used for prostate cancer diagnosis.
The authors concluded that prostate massage included within the Meares–Stamey four-glass localization test allows informative samples for urinary PCA3 test. The PCA3 score was found to be negative with less than the usual cutoff of 35, in all tested patients, suggesting that PCA3 test can be used as a valuable tool in patients with raised PSA and suspicion of chronic prostatitis to distinguish those patients who will really benefit from prostate biopsy. The study was published in the April 2012 edition of the journal the Prostate.
Related Links:
Hospices Civils de Lyon
Gen-Probe
Gold Member
Troponin T QC
Troponin T Quality Control
New
High Performance Centrifuge
CO336/336R
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
Latest Clinical Chem. News
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Channels
Molecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
